Buscar
CureVac NV
CVACAñadir a la lista de seguimiento
4.660USD
0.0000.00%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
1.05BCap. mercado
9.59P/E TTM
Más Datos de CureVac NV Compañía
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Información de CureVac NV
Símbolo de cotizaciónCVAC
Nombre de la empresaCureVac NV
Fecha de salida a bolsaAug 14, 2020
Director ejecutivoZehnder (Alexander)
Número de empleados825
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 14
DirecciónFriedrich-Miescher-Str. 15
CiudadTUEBINGEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísGermany
Código postal72076
Teléfono49707198830
Sitio Webhttps://www.curevac.com/
Símbolo de cotizaciónCVAC
Fecha de salida a bolsaAug 14, 2020
Director ejecutivoZehnder (Alexander)
Ejecutivos de CureVac NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+58.62%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+65.27%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+78.80%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
-100.00%
Dr. Malte Greune, Ph.D.
Dr. Malte Greune, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
--
--
Dr. Debra Barker, M.D.
Dr. Debra Barker, M.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Alexander Zehnder, M.D.
Dr. Alexander Zehnder, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Myriam Mendila, M.D.
Dr. Myriam Mendila, M.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
Mr. Thaminda Ramanayake
Mr. Thaminda Ramanayake
Chief Business Officer, Member of the Management Board
Chief Business Officer, Member of the Management Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+58.62%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+65.27%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+78.80%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
-100.00%
Dr. Malte Greune, Ph.D.
Dr. Malte Greune, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
--
--
Dr. Debra Barker, M.D.
Dr. Debra Barker, M.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de CureVac NV?
Los cinco principales accionistas de CureVac NV son: Mr. Baron Jean Stephenne
¿Cuántas instituciones poseen acciones de CureVac NV (CVAC)?
A fecha de 2025Q4, 242 instituciones poseen acciones de CureVac NV, con un valor de mercado combinado de aproximadamente 23.52M, lo que representa el 11.47% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en 45361.00.